Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.

  • André Scheen
  • Published 2017 in Expert opinion on drug metabolism & toxicology


INTRODUCTION Combining a dipeptidyl peptidase-4 inhibitor and a sodium-glucose cotransporter type 2 inhibitor is an attractive option to treat hyperglycaemia in type 2 diabetes. Areas covered: The saxagliptin plus dapagliflozin combination is carefully analysed, focusing on: 1) pharmacokinetic properties, 2) pharmacodynamics data, and 3) results of… (More)
DOI: 10.1080/17425255.2017.1315102


5 Figures and Tables

Slides referencing similar topics